Molecular Partners AG (MOLN.SW)
CHF 3.35
(1.83%)
CHF 3.35
(1.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.65 Million CHF | -24.7% |
| 2022 | 4.85 Million CHF | -19.69% |
| 2021 | 6.03 Million CHF | -16.33% |
| 2020 | 7.21 Million CHF | 183.61% |
| 2019 | 2.54 Million CHF | 0.0% |
| 2018 | - CHF | 0.0% |
| 2017 | - CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.04 Million CHF | -9.01% |
| 2024 Q3 | 1.21 Million CHF | -9.9% |
| 2024 Q1 | 3.35 Million CHF | -8.24% |
| 2023 Q3 | 3.95 Million CHF | -7.06% |
| 2023 FY | 3.65 Million CHF | -24.7% |
| 2023 Q1 | 4.55 Million CHF | -6.16% |
| 2023 Q4 | 3.65 Million CHF | -7.59% |
| 2023 Q2 | 4.25 Million CHF | -6.57% |
| 2022 Q2 | 5.44 Million CHF | -5.17% |
| 2022 Q4 | 4.85 Million CHF | -5.79% |
| 2022 Q1 | 5.74 Million CHF | -4.92% |
| 2022 Q3 | 5.14 Million CHF | -5.45% |
| 2022 FY | 4.85 Million CHF | -19.69% |
| 2021 FY | 6.03 Million CHF | -16.33% |
| 2021 Q2 | 6.62 Million CHF | -4.26% |
| 2021 Q4 | 6.03 Million CHF | -4.66% |
| 2021 Q3 | 6.33 Million CHF | -4.45% |
| 2021 Q1 | 6.92 Million CHF | -4.07% |
| 2020 Q2 | 1.91 Million CHF | 0.0% |
| 2020 Q4 | 7.21 Million CHF | 0.0% |
| 2020 Q1 | - CHF | -100.0% |
| 2020 FY | 7.21 Million CHF | 183.61% |
| 2019 Q4 | 2.54 Million CHF | 99.14% |
| 2019 FY | 2.54 Million CHF | 0.0% |
| 2019 Q1 | 1.9 Million CHF | 0.0% |
| 2019 Q2 | 3.15 Million CHF | 65.95% |
| 2019 Q3 | 1.27 Million CHF | -59.53% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 FY | - CHF | 0.0% |
| 2017 FY | - CHF | 0.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2017 Q1 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Addex Therapeutics Ltd | 344.33 Thousand CHF | -960.592% |
| BB Biotech AG | 304.9 Million CHF | 98.802% |
| Basilea Pharmaceutica AG | 128.6 Million CHF | 97.16% |
| Evolva Holding SA | - CHF | -Infinity% |
| Idorsia Ltd | 1.2 Billion CHF | 99.697% |
| Kuros Biosciences AG | 5.51 Million CHF | 33.817% |
| Relief Therapeutics Holding AG | 4.31 Million CHF | 15.286% |
| Santhera Pharmaceuticals Holding AG | 25.06 Million CHF | 85.428% |